Kidney Cancer

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

The holiday season is here, so here’s a festive poem to remind us that cancer should not control us during this time.

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.

Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with cT1a RCC.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.